Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Treat Metastatic Pancreatic Ductal Adenocarcinoma

뉴스 본문을 불러오고 있어요.

Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Treat Metastatic Pancreatic Ductal Adenocarcinoma | 웨이프 WAPE

Revolution Medicines' New Drug Application For Daraxonrasib Receives FDA Acceptance For Review To Treat Metastatic Pancreatic Ductal Adenocarcinoma

기사 요약

관련 종목

댓글 —